Metagenomi Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference “RNA at the Bench and Bedside IV”
December 11 2024 - 6:30PM
Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines
company committed to developing curative therapeutics for patients
using its proprietary gene editing toolbox, today presented a talk
titled “Specific and efficient genome editing with
metagenomics-derived tools for in vivo and ex vivo therapeutic
applications” at the Nature Conference: RNA at the Bench and
Bedside IV.
“We believe the value proposition for single-dose gene editing
therapies requires exquisite specificity characterization to ensure
safety and efficacy. Today’s presentation highlights the precision
of Metagenomi’s next-generation nucleases and ABEs, discovered
through the company’s proprietary metagenomics platform and
tailored for both in vivo and ex vivo therapeutic applications,”
said Alan Brooks, SVP and Head of Preclinical. “MGX-001,
Metagenomi’s development candidate for hemophilia A, which utilizes
the novel nuclease MG29-1, exhibits no identifiable off-target
editing using a series of orthogonal assays employed to evaluate
potential off-target sites in the genome. The MG29-1 nuclease
targeting the albumin safe harbor locus showed no evidence of
translocations in primary human hepatocytes. For Metagenomi’s novel
next-generation ABE for ex vivo cell therapy indications via
multiplex editing, the data showed no detectable translocations and
no significant genomic base composition differences in primary
T-cells when compared to unedited cells. These examples demonstrate
our strong capabilities in developing highly specific
next-generation gene editing tools and support the company’s
ability to potentially progress these systems toward the clinic for
the benefit of patients.”
About Metagenomi
Metagenomi is a precision genetic medicines company committed to
developing curative therapeutics for patients using its
proprietary, comprehensive metagenomics-derived toolbox. Metagenomi
is harnessing the power of metagenomics, the study of genetic
material recovered from the natural environment, to unlock four
billion years of microbial evolution to discover and develop a
suite of novel editing tools capable of correcting any type of
genetic mutation found anywhere in the genome. Its comprehensive
genome editing toolbox includes programmable nucleases, base
editors, and RNA and DNA-mediated integration systems (including
prime editing systems and clustered regularly interspaced short
palindromic repeat associated transposases (CAST)). Metagenomi
believes its diverse and modular toolbox positions the company to
access the entire genome and select the optimal tool to unlock the
full potential of genome editing for patients. For more
information, please visit https://metagenomi.co.
Cautionary Note Regarding Forward‐Looking
Statements
This press release contains “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, each as
amended. Such statements, which are often indicated by terms such
as “anticipate,” “believe,” “could,” “estimate,” “expect,”
“goal,” “intend,” “look forward to,” “may,” “plan,”
“potential,” “predict,” “project,” “should,” “will,” “would”
and similar expressions, include, but are not limited to, any
statements relating to our growth strategy and product development
programs, including the timing of and our ability to conduct
IND-enabling studies, make regulatory filings such as INDs,
statements concerning the potential of therapies and product
candidates, and any other statements that are not historical facts.
Forward-looking statements are based on management’s current
expectations and are subject to risks and uncertainties that could
negatively affect our business, operating results, financial
condition, and stock value. Factors that could cause actual results
to differ materially from those currently anticipated include:
risks relating to our growth strategy; our ability to obtain,
perform under, and maintain financing and strategic agreements and
relationships; risks relating to the results of research and
development activities; risks relating to the timing of starting
and completing clinical trials; uncertainties relating to
preclinical and clinical testing; our dependence on third party
suppliers; our ability to attract, integrate and retain key
personnel; the early stage of products under development; our need
for substantial additional funds; government regulation; patent and
intellectual property matters; competition; as well as other risks
described in “Risk Factors,” in our most recent Form 10-K and our
most recent 10-Qs on file with the Securities and Exchange
Commission. We expressly disclaim any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in our
expectations or any changes in events, conditions or circumstances
on which any such statement is based, except as required by law,
and we claim the protection of the safe harbor for forward-looking
statements contained in the Private Securities Litigation Reform
Act of 1995.
Contact:Simon Harnest - CIO, SVP Investor
RelationsIR@metagenomi.co
Metagenomi (NASDAQ:MGX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Metagenomi (NASDAQ:MGX)
Historical Stock Chart
From Dec 2023 to Dec 2024